View Future GrowthJerusalem Pharmaceuticals 過去の業績過去 基準チェック /46Jerusalem Pharmaceuticalsは、平均年間10.4%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間8.1% 1.2%収益成長率で 成長しています。 Jerusalem Pharmaceuticalsの自己資本利益率は11.4%であり、純利益率は20.4%です。主要情報10.44%収益成長率10.44%EPS成長率Pharmaceuticals 業界の成長12.39%収益成長率1.15%株主資本利益率11.42%ネット・マージン20.37%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Mar 31Jerusalem Pharmaceuticals Co. Ltd. to Report Q1, 2026 Results on Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report Q1, 2026 results on Apr 15, 2026お知らせ • Feb 25Jerusalem Pharmaceuticals Co. Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026お知らせ • Dec 17Jerusalem Pharmaceuticals Co. Ltd. to Report First Half, 2025 Results on Dec 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced that they will report first half, 2025 results on Dec 29, 2025Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: US$0.053 (vs US$0.083 in 2Q 2023)Second quarter 2024 results: EPS: US$0.053 (down from US$0.083 in 2Q 2023). Revenue: US$8.68m (down 7.0% from 2Q 2023). Net income: US$953.3k (down 36% from 2Q 2023). Profit margin: 11% (down from 16% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.Reported Earnings • Jun 16First quarter 2024 earnings released: EPS: US$0.015 (vs US$0.082 in 1Q 2023)First quarter 2024 results: EPS: US$0.015 (down from US$0.082 in 1Q 2023). Revenue: US$7.90m (down 16% from 1Q 2023). Net income: US$273.0k (down 82% from 1Q 2023). Profit margin: 3.5% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: US$0.083 (vs US$0.063 in 2Q 2022)Second quarter 2023 results: EPS: US$0.083 (up from US$0.063 in 2Q 2022). Revenue: US$9.33m (down 10% from 2Q 2022). Net income: US$1.49m (up 33% from 2Q 2022). Profit margin: 16% (up from 11% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.すべての更新を表示Recent updatesNew Risk • Jun 19New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.1% average weekly change).Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 11 non-independent directors. Director Haitham Mohammed Masrouji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 18Jerusalem Pharmaceuticals Co. Ltd. Announces Board ChangesJerusalem Pharmaceuticals Co. Ltd. announced that at the ordinary General Assembly meeting held on April 15, 2026, Approval of the resignation of Dr. Samir Al-Khatib from the Board of Directors and was replaced by Dr. Haitham Masrouji as a member of the Board of Directors.お知らせ • Mar 31Jerusalem Pharmaceuticals Co. Ltd. to Report Q1, 2026 Results on Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report Q1, 2026 results on Apr 15, 2026お知らせ • Mar 18Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividendJerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.1500 per share, ex-date on April 16, 2026 and record date on April 19, 2026.お知らせ • Mar 12Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026. Location: ramallah Palestinian Authorityお知らせ • Feb 25Jerusalem Pharmaceuticals Co. Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026お知らせ • Dec 17Jerusalem Pharmaceuticals Co. Ltd. to Report First Half, 2025 Results on Dec 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced that they will report first half, 2025 results on Dec 29, 2025Board Change • Jun 10No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 15Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025. Location: ramallah Palestinian Authorityお知らせ • Mar 22Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividend, payable on June 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.0800 per share payable on June 29, 2025, ex-date on April 30, 2025 and record date on May 04, 2025.お知らせ • Mar 21Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025. Location: ramallah Palestinian AuthorityBoard Change • Feb 12No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: US$0.053 (vs US$0.083 in 2Q 2023)Second quarter 2024 results: EPS: US$0.053 (down from US$0.083 in 2Q 2023). Revenue: US$8.68m (down 7.0% from 2Q 2023). Net income: US$953.3k (down 36% from 2Q 2023). Profit margin: 11% (down from 16% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.Reported Earnings • Jun 16First quarter 2024 earnings released: EPS: US$0.015 (vs US$0.082 in 1Q 2023)First quarter 2024 results: EPS: US$0.015 (down from US$0.082 in 1Q 2023). Revenue: US$7.90m (down 16% from 1Q 2023). Net income: US$273.0k (down 82% from 1Q 2023). Profit margin: 3.5% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 14Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 21 May 2024. Payment date: 21 July 2024. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.9%).Board Change • Jan 15No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 04No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: US$0.083 (vs US$0.063 in 2Q 2022)Second quarter 2023 results: EPS: US$0.083 (up from US$0.063 in 2Q 2022). Revenue: US$9.33m (down 10% from 2Q 2022). Net income: US$1.49m (up 33% from 2Q 2022). Profit margin: 16% (up from 11% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Board Change • Jul 11No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 11Upcoming dividend of US$0.15 per share at 2.9% yieldEligible shareholders must have bought the stock before 18 April 2023. Payment date: 18 June 2023. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.1%). Higher than average of industry peers (1.8%).Board Change • Jan 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Oct 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jun 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 05No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 05Upcoming dividend of US$0.12 per shareEligible shareholders must have bought the stock before 12 April 2022. Payment date: 12 June 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.1%). Higher than average of industry peers (1.7%).Board Change • Jan 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • May 23Upcoming dividend of US$0.08 per shareEligible shareholders must have bought the stock before 30 May 2021. Payment date: 26 July 2021. Trailing yield: 3.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.4%).Is New 90 Day High Low • Mar 11New 90-day high: US$2.88The company is up 3.0% from its price of US$2.80 on 02 December 2020. The Palestinian Territory, Occupied market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Dec 20New 90-day high: US$2.85The company is up 14% from its price of US$2.50 on 22 September 2020. The Palestinian Territory, Occupied market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.Is New 90 Day High Low • Nov 12New 90-day high: US$2.60The company is up 5.0% from its price of US$2.47 on 12 August 2020. The Palestinian Territory, Occupied market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.Is New 90 Day High Low • Oct 22New 90-day high: US$2.58The company is up 7.0% from its price of US$2.41 on 21 July 2020. The Palestinian Territory, Occupied market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.収支内訳Jerusalem Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史PLSE:JPH 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26501013231 Dec 25491013130 Sep 25471013130 Jun 2544813131 Mar 2542712131 Dec 2440512130 Sep 2437412030 Jun 2438512031 Mar 2438612131 Dec 2340712130 Sep 2343913230 Jun 2344812231 Mar 2345812231 Dec 2246713230 Sep 2246813230 Jun 2247813231 Mar 2247713231 Dec 2146713230 Sep 2141412230 Jun 2140412231 Mar 2137311131 Dec 2036411130 Sep 2036511130 Jun 2035510131 Mar 2035610131 Dec 1934510130 Sep 1932410130 Jun 193249131 Mar 193159131 Dec 183158130 Sep 183269130 Jun 182869131 Mar 183069131 Dec 173068130 Sep 172857130 Jun 173057131 Mar 172857131 Dec 162637130 Sep 162419130 Jun 162418131 Mar 162418131 Dec 152628130 Sep 1526471質の高い収益: JPH 非現金収入 のレベルが高いです。利益率の向上: JPHの現在の純利益率 (20.4%)は、昨年(16.4%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: JPHの収益は過去 5 年間で年間10.4%増加しました。成長の加速: JPHの過去 1 年間の収益成長率 ( 48.9% ) は、5 年間の平均 ( 年間10.4%を上回っています。収益対業界: JPHの過去 1 年間の収益成長率 ( 48.9% ) はPharmaceuticals業界8.7%を上回りました。株主資本利益率高いROE: JPHの 自己資本利益率 ( 11.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/13 11:59終値2026/07/13 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Jerusalem Pharmaceuticals Co. Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 31Jerusalem Pharmaceuticals Co. Ltd. to Report Q1, 2026 Results on Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report Q1, 2026 results on Apr 15, 2026
お知らせ • Feb 25Jerusalem Pharmaceuticals Co. Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026
お知らせ • Dec 17Jerusalem Pharmaceuticals Co. Ltd. to Report First Half, 2025 Results on Dec 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced that they will report first half, 2025 results on Dec 29, 2025
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: US$0.053 (vs US$0.083 in 2Q 2023)Second quarter 2024 results: EPS: US$0.053 (down from US$0.083 in 2Q 2023). Revenue: US$8.68m (down 7.0% from 2Q 2023). Net income: US$953.3k (down 36% from 2Q 2023). Profit margin: 11% (down from 16% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.
Reported Earnings • Jun 16First quarter 2024 earnings released: EPS: US$0.015 (vs US$0.082 in 1Q 2023)First quarter 2024 results: EPS: US$0.015 (down from US$0.082 in 1Q 2023). Revenue: US$7.90m (down 16% from 1Q 2023). Net income: US$273.0k (down 82% from 1Q 2023). Profit margin: 3.5% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: US$0.083 (vs US$0.063 in 2Q 2022)Second quarter 2023 results: EPS: US$0.083 (up from US$0.063 in 2Q 2022). Revenue: US$9.33m (down 10% from 2Q 2022). Net income: US$1.49m (up 33% from 2Q 2022). Profit margin: 16% (up from 11% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
New Risk • Jun 19New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.1% average weekly change).
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 11 non-independent directors. Director Haitham Mohammed Masrouji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 18Jerusalem Pharmaceuticals Co. Ltd. Announces Board ChangesJerusalem Pharmaceuticals Co. Ltd. announced that at the ordinary General Assembly meeting held on April 15, 2026, Approval of the resignation of Dr. Samir Al-Khatib from the Board of Directors and was replaced by Dr. Haitham Masrouji as a member of the Board of Directors.
お知らせ • Mar 31Jerusalem Pharmaceuticals Co. Ltd. to Report Q1, 2026 Results on Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report Q1, 2026 results on Apr 15, 2026
お知らせ • Mar 18Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividendJerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.1500 per share, ex-date on April 16, 2026 and record date on April 19, 2026.
お知らせ • Mar 12Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026. Location: ramallah Palestinian Authority
お知らせ • Feb 25Jerusalem Pharmaceuticals Co. Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jerusalem Pharmaceuticals Co. Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026
お知らせ • Dec 17Jerusalem Pharmaceuticals Co. Ltd. to Report First Half, 2025 Results on Dec 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced that they will report first half, 2025 results on Dec 29, 2025
Board Change • Jun 10No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 15Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025. Location: ramallah Palestinian Authority
お知らせ • Mar 22Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividend, payable on June 29, 2025Jerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.0800 per share payable on June 29, 2025, ex-date on April 30, 2025 and record date on May 04, 2025.
お知らせ • Mar 21Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025. Location: ramallah Palestinian Authority
Board Change • Feb 12No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: US$0.053 (vs US$0.083 in 2Q 2023)Second quarter 2024 results: EPS: US$0.053 (down from US$0.083 in 2Q 2023). Revenue: US$8.68m (down 7.0% from 2Q 2023). Net income: US$953.3k (down 36% from 2Q 2023). Profit margin: 11% (down from 16% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.
Reported Earnings • Jun 16First quarter 2024 earnings released: EPS: US$0.015 (vs US$0.082 in 1Q 2023)First quarter 2024 results: EPS: US$0.015 (down from US$0.082 in 1Q 2023). Revenue: US$7.90m (down 16% from 1Q 2023). Net income: US$273.0k (down 82% from 1Q 2023). Profit margin: 3.5% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 14Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 21 May 2024. Payment date: 21 July 2024. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.9%).
Board Change • Jan 15No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 04No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: US$0.083 (vs US$0.063 in 2Q 2022)Second quarter 2023 results: EPS: US$0.083 (up from US$0.063 in 2Q 2022). Revenue: US$9.33m (down 10% from 2Q 2022). Net income: US$1.49m (up 33% from 2Q 2022). Profit margin: 16% (up from 11% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 11No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 11Upcoming dividend of US$0.15 per share at 2.9% yieldEligible shareholders must have bought the stock before 18 April 2023. Payment date: 18 June 2023. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.1%). Higher than average of industry peers (1.8%).
Board Change • Jan 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Oct 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jun 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 05No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 05Upcoming dividend of US$0.12 per shareEligible shareholders must have bought the stock before 12 April 2022. Payment date: 12 June 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.1%). Higher than average of industry peers (1.7%).
Board Change • Jan 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • May 23Upcoming dividend of US$0.08 per shareEligible shareholders must have bought the stock before 30 May 2021. Payment date: 26 July 2021. Trailing yield: 3.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.4%).
Is New 90 Day High Low • Mar 11New 90-day high: US$2.88The company is up 3.0% from its price of US$2.80 on 02 December 2020. The Palestinian Territory, Occupied market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Dec 20New 90-day high: US$2.85The company is up 14% from its price of US$2.50 on 22 September 2020. The Palestinian Territory, Occupied market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.
Is New 90 Day High Low • Nov 12New 90-day high: US$2.60The company is up 5.0% from its price of US$2.47 on 12 August 2020. The Palestinian Territory, Occupied market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Oct 22New 90-day high: US$2.58The company is up 7.0% from its price of US$2.41 on 21 July 2020. The Palestinian Territory, Occupied market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.